ReviewExpert opinion on investigational drugs2010
Novel targets for the treatment of autosomal dominant polycystic kidney disease.
Review in Expert opinion on investigational drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.QJM : monthly journal of the Association of Physicians · 2020Trial
- Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.Clinical journal of the American Society of Nephrology : CJASN · 2014Trial
- Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study.BMC nephrology · 2010Trial
- Metabolism-based approaches for autosomal dominant polycystic kidney disease.Frontiers in molecular biosciences · 2023Review
- Organoid-on-a-chip model of human ARPKD reveals mechanosensing pathomechanisms for drug discovery.Science advances · 2022Article
- Aquatic models of human ciliary diseases.Genesis (New York, N.Y. : 2000) · 2021Review
- Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Apoptosis and autophagy in polycystic kidney disease (PKD).Cellular signalling · 2020Review
- Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions.Journal of cellular physiology · 2019Review
- Drug prioritization using the semantic properties of a knowledge graph.Scientific reports · 2019Article
- Autophagy and Tubular Cell Death in the Kidney.Seminars in nephrology · 2016Review
- Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease.Physiological reports · 2015Article
- Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.American journal of physiology. Renal physiology · 2014Article
- Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013Article
- Cystic kidney diseases: many ways to form a cyst.Pediatric nephrology (Berlin, Germany) · 2013Review
- CFTR inhibitors.Current pharmaceutical design · 2013Review
- CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.Cell cycle (Georgetown, Tex.) · 2012Article
- Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.Kidney research and clinical practice · 2012Review
- Review
- Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models.American journal of physiology. Renal physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
importance of the fieldAutosomal dominant (AD) polycystic kidney disease (PKD) is the most common life-threatening hereditary disorder. There is currently no therapy that slows or prevents cyst formation and kidney enlargement in humans. An increasing number of animal studies have advanced our understanding of molecular and cellular targets of PKD. AREAS COVERED IN THE REVIEW: The purpose of this review is to summarize the molecular and cellular targets involved in cystogenesis and to update on the promising therapies that are being developed and tested based on knowledge of these molecular and cellular targets. WHAT THE READER WILL GAIN: Insight into the pathogenesis of PKD and how a better understanding of the pathogenesis of PKD has led to the development of potential therapies to inhibit cyst formation and/or growth and improve kidney function. TAKE HOME MESSAGE: The results of animal studies in PKD have led to the development of clinical trials testing potential new therapies to reduce cyst formation and/or growth. A vasopressin V2 receptor antagonist, mTOR inhibitors, blockade of the renin-angiotensin system and statins that reduce cyst formation and improve renal function in animal models of PKD are being tested in interventional studies in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.